Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 69Recurrence 20Neoplasms, Plasma Cell 6Neoplasms 4Lymphoma 3Small Cell Lung Carcinoma 2Waldenstrom Macroglobulinemia 1Renal Insufficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Kidney Failure, Chronic 1Hodgkin Disease 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Neoplasms 1Blast Crisis 1

Interventions

zanubrutinib 9ibrutinib 9Rituximab 5idelalisib 4venetoclax 3pirtobrutinib 3ublituximab 2bazlitoran 2acalabrutinib 2Dexamethasone 2ARQ531 2umbralisib 1selinexor 1sapanisertib 1pomalidomide 1perifosine 1pembrolizumab 1ontuxizumab 1ofatumumab 1obinutuzumab 1mavorixafor 1loncastuximab tesirine 1fludarabine 1epratuzumab 1enzastaurin 1carfilzomib 1brexucabtagene autoleucel 1WW Domain-Containing Oxidoreductase 1Voriconazole 1Vitamin B 12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Waldenstrom Macroglobulinemia × carfilzomib × Clear all
NCT00150462 2017-05-02

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Amgen

Phase 1 Completed
48 enrolled 26 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡